
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Tempest Therapeutics Inc (TPST)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TPST (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $9
1 Year Target Price $9
0 | Strong Buy |
0 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.14% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.09M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 2 | Beta -2.31 | 52 Weeks Range 5.35 - 20.67 | Updated Date 08/15/2025 |
52 Weeks Range 5.35 - 20.67 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.52 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.28 | Actual -2.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.34% | Return on Equity (TTM) -322.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36475726 | Price to Sales(TTM) - |
Enterprise Value 36475726 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.31 | Shares Outstanding 4440160 | Shares Floating 4139962 |
Shares Outstanding 4440160 | Shares Floating 4139962 | ||
Percent Insiders 0.11 | Percent Institutions 13.08 |
Upturn AI SWOT
Tempest Therapeutics Inc
Company Overview
History and Background
Tempest Therapeutics Inc. is a clinical-stage oncology company focused on developing therapies that combine both tumor-directed and immune-mediated mechanisms. Founded in 2016, it has focused on advancing its pipeline through clinical trials.
Core Business Areas
- Drug Development: Focused on discovering, developing, and commercializing small molecule therapeutics that modulate selective targets in the tumor microenvironment. Currently, the focus is on its lead drug candidate, TPST-1120.
Leadership and Structure
Dr. Sam Whiting serves as President and CEO. The company has a board of directors overseeing its strategic direction and operations. The structure includes research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- TPST-1120: An oral, selective PPARu03b1 antagonist being developed for liver cancer and other solid tumors. TPST-1120 is currently in clinical trials (Phase 1b/2). As a clinical-stage asset, it doesn't yet have market share or revenue. Competitors include other companies developing therapies for advanced solid tumors.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and growing, driven by increasing cancer incidence and advances in targeted therapies and immunotherapies. The market is highly competitive, with many companies developing novel cancer treatments.
Positioning
Tempest Therapeutics aims to address unmet needs in cancer treatment by developing therapies that modulate the tumor microenvironment. Its competitive advantage lies in its targeted approach to PPARu03b1 antagonism and its potential to combine with other therapies.
Total Addressable Market (TAM)
The global oncology market is estimated to be several hundred billion USD. Tempest's initial target indication of liver cancer represents a multi-billion dollar market opportunity. Their positioning relies on clinical success to capture part of this TAM.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting PPARu03b1
- Clinical-stage pipeline
- Experienced management team
Weaknesses
- Reliance on a single lead asset (TPST-1120)
- No current revenue stream
- High cash burn rate associated with drug development
Opportunities
- Positive clinical trial results for TPST-1120
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer indications
Threats
- Clinical trial failures
- Competition from established oncology therapies
- Regulatory hurdles
- Funding risks due to market volatility
Competitors and Market Share
Key Competitors
- GILD
- BMY
- MRK
Competitive Landscape
Tempest faces significant competition from established pharmaceutical companies with larger resources and broader oncology portfolios. Their success depends on differentiating TPST-1120 and demonstrating its efficacy in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, Tempest's historical growth has been marked by the progress of its clinical trials and milestones in drug development.
Future Projections: Future growth is contingent on the successful development and commercialization of TPST-1120 and any other pipeline candidates. Analyst projections are based on the potential market for these therapies.
Recent Initiatives: Recent initiatives include advancing TPST-1120 through clinical trials and exploring potential partnerships for further development and commercialization.
Summary
Tempest Therapeutics is a high-risk, high-reward clinical-stage company. Its success depends on the positive clinical trial outcomes of its lead drug candidate, TPST-1120. While it faces competition from larger pharmaceutical companies and regulatory hurdles, successful development could lead to significant growth and market opportunities. Monitoring cash flow, clinical milestones, and market sentiment is crucial for investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tempest Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is estimated and may vary. All financial data is based on the most recent available information, which may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tempest Therapeutics Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2012-11-12 | CEO, President & Director Mr. Stephen R. Brady J.D., LLM | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.tempesttx.com |
Full time employees 24 | Website https://www.tempesttx.com |
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.